Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients

NCT01278342 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Acromegaly

Interventions

DRUG: Sandostatin LAR
DRUG: pegvisomant
DRUG: cabergoline

Sponsor

Novartis Pharmaceuticals